Eli Lilly and Company– tag –
-
Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout
Samsung Biologics South Korea Overview Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide G... -
Eli Lilly Forges Partnership with Gateway Labs Alumnus to Develop Trans-Amplifying RNA Vaccine Platform for Infectious Diseases
Fierce Biotech USA Overview Eli Lilly has announced a strategic partnership with a Gateway Labs alumnus company to advance a trans-amplifying RNA (taRNA) vaccine platform for infectious diseases. This collaboration aims to bolster Lilly'... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
PTC Therapeutics and Eli Lilly to Acquire Sangamo Assets for Up to $264M in Bankruptcy Auction, Bolstering Rare Disease Pipelines
Endpoints News USA Overview PTC Therapeutics and Eli Lilly are set to acquire parts of the bankrupt gene editing biotech Sangamo for up to $264 million following an auction. PTC Therapeutics will acquire Sangamo's Fabry disease candidate... -
SpaceX/xAI Acquires AI Coding Platform Cursor Amidst $600 Billion Pending M&A Deals
DealRoom.net USA Overview As of August 2026, approximately 20 M&A deals valued at $600 billion are pending completion. Notably, SpaceX acquired AI coding platform Cursor, to be integrated into xAI's computing and model stack, which S... -
Biopharma’s Evolving Blueprint: AGC Biologics Expands Global Capacity, Enzene Drives Continuous Manufacturing Adoption
Pharma Manufacturing USA Overview This news digest highlights several pivotal developments in the biopharmaceutical manufacturing sector, showcasing an industry-wide acceleration towards enhanced capacity and technological innovation. Ke... -
Resilience and Eli Lilly Invest $750 Million to Boost U.S. Medicine Supply, Expanding Biologics, Cell Therapy, and Aseptic Manufacturing
Resilience USA Overview Resilience has announced a $750 million investment in new pharmaceutical manufacturing in Ohio, expanding its strategic partnership with Eli Lilly to bolster the U.S. medicine supply. Resilience operates as a comp... -
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap... -
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Isomorphic Labs Secures $2.9 Billion in Partnerships with Eli Lilly and Novartis, Validating AI Drug Discovery Platform
GeneOnline Taiwan Overview Isomorphic Labs, a Google DeepMind spin-out, has solidified its AI drug discovery platform's value through significant partnerships totaling $2.9 billion with Eli Lilly ($1.7B) and Novartis ($1.2B). Concurrentl...
